Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Neutrophil-albumin ratio (NPAR) has been identified as a prognostic indicator of mortality from various diseases: however, its association with the progression of chronic kidney disease and the development of cardiovascular complications is insufficiently studied. The aim of this research was to examine the relationship between serum NPAR and the prognosis of patients with chronic kidney disease, stage I-V.
The study included a group of 90 patients with CKD who did not initially start treatment with any of the methods for replacing renal function and who had no history of cardiovascular or cerebrovascular events. Their average age was 56.09±10.8 years, men were more often 62.22%, compared to women 37.8%. According to GFR values, patients were divided into two groups: group G1, GFR ≥ 60 ml/min/1.73m2, 51 of them, and group G2, GFR < 60 ml/min/1.73m2, 39 patients. We retrospectively analyzed the outcome of patients after five years of follow-up. Inflammation biomarkers were determined for all patients: NLR (Ne/Ly), SII(Tr x Ne/Ly), SIRI (Ne x Mo)/Ly, IAR (Il6/Albumin) and NPAR(%Ne/albumin) in order to assess their association with CKD progression and death.
After five years of follow-up in a study of 90 subjects with CKD, 54 (60%) remained. Due to the development of terminal renal failure, 30 (33.3%) started treatment: hemodialysis (HD) 22 (24.44%), peritoneal dialysis (PD) 4 (4.44%) and kidney transplantation (Tx) 4 (4.44%). The fatal outcome occurred in 6 (6.66%). The cause of death in 4 (66.66%) was a cardiovascular event, and in 2 (33.33%) a malignant disease. Progression of CKD was more common in group II, 27 (69.23%) compared to group I: 8 (15.68%). The fatal outcome occurred in 6 (6.66%). The cause of death in 4 (66.66%) was a cardiovascular event, and in 2 (33.33%) a malignant disease. Progression of CKD was more common in group II, 27 (69.23%) compared to group I: 8 (15.68%). Examining the association of inflammation biomarkers between the group of patients without CKD progression and the group of patients who started treatment: HD, PD or Tx verified statistical significance for NPAR (p <0.0001), NLR, PLR and SII (p<0.001) and SIRI (p<0.05). Between the group without CKD progression and the group of patients with a fatal outcome, statistical significance was verified for: SII (p < 0.0001), PLR, SIRI and NPAR (p<0.05), and in patients with a fatal outcome from CVD: NPAR p<0.0001, SII p<0.001 and PLR <0.05. Analysis of patients according to gender, age, body mass index and smoking status did not verify statistical significance with biomarkers of inflammation.
NPAR can serve as a biomarker of chronic kidney disease progression and a prognostic factor of cardiovascular mortality.
